 we report on our financial results for the second quarter of 2023 and summarize recent achievements in recent corporate updates.  we report a 77% year-over-year increase in total revenues of approximately $60.1 million in the second quarter of 2023 as compared to approximately $33.9 million in the first quarter of 2023.  our gross profit for the 3 months ended June 30, 2023, was $16.7 million as compared to $7.8 million for the same period of a year ago, and this represents an increase of $8.9 million or 77% year-over-year.  our adjusted net loss was $3.6 million for the second quarter of 2023, a significant period-over-period improvement.  we grew adjusted EBITDA to $6.4 million for the 3 months ended 2023, as compared to an adjusted EBITDA loss of $6.3 million the same period of a year ago.  we anticipate continued adjusted EBITDA growth throughout this year and beyond.  the company has made progress with development scale and laboratory analysis with the potential to increase both peak revenues and margin potential upon the successful validation of commercial scale production and receipt of requisite regulatory approvals.  finally,